Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08JRT
|
||||
Former ID |
DCL000621
|
||||
Drug Name |
RhApo2L/TRAIL
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 1/2 | [546989] | ||
Company |
Amgen
|
||||
Target and Pathway | |||||
Target(s) | Tumor necrosis factor receptor superfamily member 10A | Target Info | Agonist | [525341], [550250] | |
Tumor necrosis factor receptor superfamily member 10B | Target Info | Agonist | [525341], [550250] | ||
WikiPathways | miR-targeted genes in lymphocytes - TarBase | ||||
Apoptosis Modulation and SignalingWP707:DNA Damage Response | |||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
Apoptosis | |||||
miR-targeted genes in squamous cell - TarBase | |||||
miR-targeted genes in muscle cell - TarBase | |||||
miR-targeted genes in epithelium - TarBase | |||||
Extrinsic Pathway for Apoptosis | |||||
Apoptosis Modulation and Signaling | |||||
miRNA Regulation of DNA Damage Response | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.